🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT06440395
Recruiting Observational

Small Steps for Big Changes - Healthy Cities Implementation Science

NCT06440395 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2024-06-03
Last updated
2026-08-03

Condition(s) studied

PreDiabetes

Investigational drug(s) / intervention(s)

Behavioural: Small Steps for Big Changes Diabetes Prevention Program

Behavioural: Small Steps for Big Changes Diabetes Prevention Program: The 4-week behaviour change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 4-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the YMCA). The supervised session will include brief behavioural counselling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.

Study summary

Small Steps for Big Changes (SSBC) is a diet and exercise counselling program that significantly reduces the risk of developing Type 2 Diabetes (T2D). In partnership with YMCAs in Canada spanning 8 provinces, the aim of this study is to scale-up program delivery and evaluate the implementation and effectiveness of SSBC. To evaluate implementation, the number of staff trained/patients enrolled, attendance, sessions delivered as planned, delivery costs, and number of sites continuing to deliver the program will be examined. To evaluate program effectiveness, changes in patient health (e.g., T2D status, blood glucose, weight, exercise, diet) will be measured over 2 years following program completion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Patients Inclusion Criteria: * Community-dwelling adults aged 18 years or older * able to read and speak English * has prediabetes assessed by one of the following means: (a) physician-diagnosed prediabetes, (b) HbA1c values between 5.7 - 6.4% (American Diabetes Association, 2012), (c) an American Diabetes Association risk questionnaire score indicating increased risk (\>5) * Individuals who have previously been diagnosed with type 2 diabetes but who are in remission (defined as achieving glycated hemoglobin (A1C) of \< 6.4% without any diabetes-related medications for a minimum of 3 months) will be eligible to participate. Exclusion Criteria: \- Patients currently diagnosed type 2 diabetes with an HbA1c of 6.5% or greater. Organizational partners Inclusion criteria: \- Senior leadership and/or management of our Canadian YMCA delivery partner organizations Exclusion criteria: N/A Site leads/managers Inclusion criteria: \- YMCA staff who manage/coordinate programs (e.g., general manager of health programs) for each site willing to act as SSBC site lead champion. Exclusion criteria: N/A Coaches Inclusion criteria: Site staff certified as SSBC coaches to deliver the program. Exclusion criteria: N/A

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
Castle Downs Family YMCA Edmonton Alberta Not Yet Recruiting
Health and Exercise Psychology Laboratory Kelowna British Columbia Recruiting
Prince George Family YMCA Prince George British Columbia Not Yet Recruiting
Tong Louie Family YMCA Surrey British Columbia Not Yet Recruiting
YMCA of Brandon Health and Fitness Centre Brandon Manitoba Not Yet Recruiting
Elmwood-Kildonan Winnipeg Manitoba Not Yet Recruiting
Saint John Regional Y Saint John New Brunswick Not Yet Recruiting
Ches Penney Family YMCA St. John's Newfoundland and Labrador Not Yet Recruiting
John W. Lindsay YMCA Halifax Nova Scotia Not Yet Recruiting
YMCA 3 Rivers Kitchener Ontario Not Yet Recruiting
YMCA of Greater Toronto - Scarborough Health and Fitness Centre Scarborough Village Ontario Not Yet Recruiting
YMCA of Regina Health, Fitness and Aquatics Centre Regina Saskatchewan Not Yet Recruiting

More University of British Columbia trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06440395 on ClinicalTrials.gov ↗ ← All trials in Canada